title: Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.
abstract: Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. The aim of the present study was to evaluate, in an open-label pilot study, the effects and safety of very small doses of aripiprazole on L-dopa-induced dyskinesia of a group of PD patients who did not show a significant clinical benefit by pharmacological treatment with amantadine and mirtazapine. Twelve PD patients with peak-dose LID were enrolled in a period of 1 year. Aripiprazole dosage was of 0.625 mg/day. The ten patients who continued taking aripiprazole displayed a significant decrease in the intensity and frequency of dyskinesias in all parts of the body, particularly in trunk movements (AIMS score T(0) = 14.1 +/- 3.6 vs. final score 2.4. +/- 2.6; P = 0.005). Our study suggests that aripiprazole at very low doses is tolerated and could be efficacy in treating LID.
authors.affiliation: Centro Parkinson D.A.I. Neurologia e Psichiatria Policlinico Universitario Umberto I degrees, Sapienza Università di Roma, Viale dell'Università 30, Rome 00185, Italy. giuseppe.meco@uniroma1.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Meco
authors.forename: Paola
authors.initials: P
authors.lastname: Stirpe
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Edito
authors.forename: Carlo
authors.initials: C
authors.lastname: Purcaro
authors.forename: Marcella
authors.initials: M
authors.lastname: Valente
authors.forename: Silvia
authors.initials: S
authors.lastname: Bernardi
authors.forename: Nicola
authors.initials: N
authors.lastname: Vanacore
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000368:Aged; D000369:Aged, 80 and over; D000547:Amantadine / Q000494:pharmacology; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000068180:Aripiprazole; D001479:Basal Ganglia / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions / Q000502:physiology; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000037:antagonists & inhibitors*; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives / Q000494:pharmacology; D008875:Middle Aged; D000078785:Mirtazapine; D010865:Pilot Projects; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D015363:Quinolones / Q000008:administration & dosage* / Q000009:adverse effects; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000378:metabolism; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000317:Adrenergic alpha-Antagonists; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D008803:Mianserin; D007980:Levodopa; D000068180:Aripiprazole; D000078785:Mirtazapine; D000547:Amantadine; D004298:Dopamine